OncoMatch/Clinical Trials/NCT07162298
Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients
Is NCT07162298 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
Investigators plans to conduct a randomized, open, single center clinical study of Dragon Boat Race versus family unsupervised training to improve the physical function and quality of life in breast cancer patients to compare the effects of organized and supervised short-term dragon boat training versus unsupervised home training on body composition, physical function, and quality of life in women after breast cancer surgery. Participants will be assigned to the following intervention protocols at a 1:1 ratio:Dragon Boat Training Group (DB): Conduct 12-week dragon boat training under the guidance of professional coaches.Home-based Unsupervised Training Group (HG): Perform exercises at home independently according to instructional videos for 12 weeks.The primary outcomes are to analyze differences in body composition, physical function, and quality of life.The secondary exploratory outcomes include stratified factors such as menopausal status and surgical methods
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor therapy
Exception: excluding cured malignant tumors such as carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma
Previous receipt of anti-tumor therapy or radiotherapy for any malignant tumor, excluding cured malignant tumors such as carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma
Cannot have received: anti-tumor therapy in other clinical trials
Concurrent receipt of anti-tumor therapy in other clinical trials, including but not limited to chemotherapy, endocrine therapy, biological therapy, bone-modifying agent therapy, or immune checkpoint inhibitor therapy
Lab requirements
Blood counts
absolute neutrophil count (anc) > 1.5×10⁹/l; platelet count (plt) > 75×10⁹/l; hemoglobin (hb) > 90g/l; lymphocyte count ≥ 1.5×10⁹/l
Kidney function
blood urea nitrogen/urea (bun/urea) and creatinine (cr) < 1.5×uln
Liver function
total bilirubin (tbil) < 1.5×uln; alanine aminotransferase (alt) and aspartate aminotransferase (ast) < 1.5×uln; alkaline phosphatase < 2.5×uln
Cardiac function
left ventricular ejection fraction (lvef) > 55%; fridericia-corrected qt interval (qtcf) < 470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify